BAUSCH + LOMB CORP

BLCO refers to the common stock of Bausch + Lomb Corporation, a global eye health company. The company develops, manufactures, and markets a broad range of products including contact lenses, lens care solutions, surgical devices, and pharmaceuticals for eye conditions. BLCO trades on the New York Stock Exchange and is followed by investors interested in the medical devices and eye care sector.

The latest price of BLCO stock is displayed at the top of this page and updates with market data. For the most accurate, real-time quote, check the live price feed on this stock detail page or a trusted brokerage platform. Price quotes can vary slightly depending on the data source and any delay in reporting.

Recent performance for BLCO, including daily, weekly, and year-to-date price changes, is shown in the performance section of this page. That data reflects actual market activity and is updated regularly. For context, compare BLCO's recent moves with its historical price chart and any recent company announcements, which can influence short-term performance.

Evaluating BLCO's valuation typically involves reviewing metrics such as the price-to-earnings ratio, price-to-sales ratio, and enterprise value relative to EBITDA. These measures are most useful when compared with peer companies in the medical devices and eye care industries, as well as BLCO's own historical averages. The relevant valuation ratios are available on this page's financial metrics section.

Bausch + Lomb does not currently pay a regular cash dividend on its common stock. The company has historically retained earnings to reinvest in its business, pay down debt, and fund growth initiatives. For the most current dividend status, including any future changes, review the dividend section of this page or the company's official investor relations materials.

Key risks for BLCO include competition in the eye health market, regulatory and reimbursement pressures, product liability and recalls, supply chain disruptions, and significant debt levels. The company also faces foreign exchange fluctuations and integration risks from acquisitions. These and other risk factors are described in BLCO's annual report and SEC filings, which investors can review for a complete picture.